Latest & greatest articles for Hypertension Causes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Hypertension Causes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Hypertension Causes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Hypertension Causes

1. Treatment of Secondary Hypertension Due to Endocrine Causes

Treatment of Secondary Hypertension Due to Endocrine Causes XIV. Treatment of Secondary Hypertension Due to Endocrine Causes | Hypertension Canada Guidelines Subgroup Members: Ally P.H. Prebtani, MD; Gregory Kline, MD, Ernesto L. Schiffrin, MD PhD; Andrew Don-Wauchope, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH (...) ; Sonia Butalia, BSc MD MSc; Meranda Nakhla, MD MSc Co-Chairs: Doreen M. Rabi, MD MSc, Stella S. Daskalopoulou, MD MSc DIC PhD This information is based on the Hypertension Canada guidelines published in Nerenberg, Kara A. et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. . Recommendations Treatment of hyperaldosteronism and pheochromocytoma are outlined in , respectively. Background Treatment

2018 Hypertension Canada

3. Subacute right heart failure revealing three simultaneous causes of post‐embolic pulmonary hypertension in metastatic dissemination of breast cancer (PubMed)

Subacute right heart failure revealing three simultaneous causes of post‐embolic pulmonary hypertension in metastatic dissemination of breast cancer A 72-year-old woman with history of breast cancer only treated surgically was referred to our department for pulmonary hypertension (PH) suspicion. Echocardiogram revealed elevated right ventricular systolic pressure. Computed tomography (CT) angiogram showed no pulmonary embolism (PE), but lung scan revealed two ventilation-perfusion mismatch

Full Text available with Trip Pro

2016 ESC heart failure

4. A rare cause of hypertension in pregnancy: Phaeochromocytoma (PubMed)

A rare cause of hypertension in pregnancy: Phaeochromocytoma A 26-year-old primigravida at 35 weeks' gestation was transferred to our institution from a regional hospital for management of presumed preeclampsia. Due to the labile nature of her hypertension, further investigation was undertaken which revealed a right-sided phaeochromocytoma. Alpha blockade was commenced, and an uncomplicated elective caesarean delivery was performed at 38 weeks' gestation under spinal anaesthetic. The patient (...) underwent an elective right laparoscopic adrenalectomy six weeks post-partum. This case highlights the importance of investigating young women for secondary causes of hypertension to avoid mislabelling as essential or gestational hypertension.

Full Text available with Trip Pro

2016 Obstetric medicine

5. Whom should you test for secondary causes of hypertension?

Whom should you test for secondary causes of hypertension? Whom should you test for secondary causes of hypertension? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Whom should you test for secondary causes of hypertension? View/ Open Date 2014-01 Format Metadata Abstract Evidence-based answer: It’s recommended (...) that all children and adolescents with a new diagnosis of hypertension undergo renal ultrasound and laboratory evaluation for renal pathology (strength of recommendation [SOR]: C, consensus-based guidelines). Specific diagnostic tests are recommended for newly diagnosed patients who have suspicious clinical findings suggestive of a secondary cause of hypertension based on the initial history (excess daytime sleepiness, palpitations, tremor, sweating); physical examination (abdominal bruit, thyromegaly

2014 Clinical Inquiries

6. Do Soft Drinks Cause Hypertension?

Do Soft Drinks Cause Hypertension? Do Soft Drinks Cause Hypertension? – Clinical Correlations Search Do Soft Drinks Cause Hypertension? July 8, 2011 6 min read By Ivan Saraiva, MD Faculty Peer Reviewed Sugared soft drinks are among the most heavily consumed drinks in the US. Carbonated soft drinks were first invented as a way to make “healthier” water that looked like natural carbonated waters that were found in European spas in the mountains. The name soda came from the use of bicarbonate (...) with treatment of hyperuricemia with allopurinol ( .(3). An observational study of soft drinks intake in adolescents found increased uric acid levels [4]. Although uric acid may cause hypertension and mediate some of the pathologic consequences classically associated with longstanding high blood pressure in mice, humans are more complex. Studies have been conflicting. Antagonizing or decreasing uric acid with vitamin C was not associated with a decreased risk of hypertension in the Nurses’ Health [5-8

2011 Clinical Correlations

7. Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension

Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension Article Text Therapeutics Review: atenolol may

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

8. ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension

ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension Article Text Therapeutics ACE inhibitors reduced cardiovascular events

Full Text available with Trip Pro

2004 Evidence-Based Medicine (Requires free registration)

9. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. (PubMed)

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. The acute effects of inhaled nitric oxide (NO) (40 ppm in air) on pulmonary (PVR) and systemic (SVR) vascular resistance were compared with those of an intravenous infusion of prostacyclin (24 micrograms/h) in 8 patients with severe pulmonary hypertension and 10 cardiac patients with normal values of PVR. 10 healthy volunteers were studied non-invasively. In the patients with pulmonary hypertension (...) , PVR fell significantly after inhaled NO and after prostacyclin. PVR also fell significantly in the cardiac patients after inhaled NO. Although SVR fell substantially after prostacyclin in patients with pulmonary hypertension, inhaled NO had no effect on SVR in any patient or volunteer. Inhaled NO therefore seems to be both a selective and effective pulmonary vasodilator.

1991 Lancet